B-cell Lymphoma Clinical Trial
Official title:
A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL, DLBCL and Other Non-Hodgkin B-Cell Lymphoma
This is an open label, dose escalation, phase I study to determine the recommended Phase 2 dose (PR2D) by assessing the DLT, safety and efficacy of AC0010 in patients with B-cell lymphoma.
This is an open label, dose escalation, phase I study to determine the PR2D by assessing the DLT, safety and efficacy of AC0010 in patients with B-cell lymphoma. This study includes two parts. During Part 1 Dose Escalation, the "3+3" design will be applied. Dose escalation will begin at dose level 1 = 400 mg. This dose escalation will be followed by an exploratory expansion phase in 3 or 4 groups of 15~41 patients each (CLL group, MCL group, non-germinal center B cell-like DLBCL group, and/or FL/WM(macroglobulinemia) group). The study will further evaluate the safety and efficacy of AC0010 in these patients in each group ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05365659 -
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
|
Phase 1 | |
| Withdrawn |
NCT05929716 -
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Recruiting |
NCT05016947 -
Venetoclax Plus Inotuzumab for B-ALL
|
Phase 1 | |
| Completed |
NCT02900716 -
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
|
Phase 1 | |
| Completed |
NCT03068416 -
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
|
Phase 2 | |
| Not yet recruiting |
NCT05014100 -
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05934838 -
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
|
Phase 1 | |
| Terminated |
NCT04023071 -
FT516 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04148430 -
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
|
Phase 2 | |
| Completed |
NCT02933320 -
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03133221 -
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT02741388 -
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
|
Phase 1 | |
| Terminated |
NCT02266147 -
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02300402 -
Detection and Characterization of Residual Masses in Lymphomas
|
||
| Terminated |
NCT00906841 -
Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00338494 -
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05487651 -
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
|
Phase 1 | |
| Withdrawn |
NCT05570188 -
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03281551 -
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
|
Phase 1 |